Castle Biosciences Inc. Chief Commercial Officer Tobin W Juvenal filed a Form 4 on August 19, 2026, reporting the sale of 1,730 shares of common stock on August 17, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 1,730 shares of Castle Biosciences common stock disposed of on August 17, 2026.
  • Weighted-average sale price: $29.59 per share, with individual trades ranging from $29.21 to $30.01.
  • Remaining ownership: 75,964 shares of common stock held directly following the transaction.
  • 10b5-1 plan: The sale was made under a Rule 10b5-1 plan adopted by the reporting person on December 10, 2025.
  • Transaction code: "S" (sale), executed in multiple trades.

Castle Biosciences CCO Share Sale Details and Plan Background

According to the filing, Tobin W Juvenal, Chief Commercial Officer of Castle Biosciences Inc. (NASDAQ:CSTL), disposed of 1,730 shares of the company's common stock on August 17, 2026. The transaction was reported as a direct sale with transaction code "S." The filing indicates that the sale was carried out in multiple trades at prices ranging from $29.21 to $30.01, inclusive, and that the price of $29.59 stated in the form reflects the weighted-average sale price across those trades.

The filing notes that the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025. The reporting person also undertakes, according to the filing, "to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected." Following the reported transaction, Juvenal's direct beneficial ownership in Castle Biosciences common stock stood at 75,964 shares. No derivative securities transactions were reported in this filing.

What Was Disclosed

The Form 4 filing discloses a sale of 1,730 Castle Biosciences common shares by the company's Chief Commercial Officer on August 17, 2026, at a weighted-average price of $29.59, conducted under a pre-established Rule 10b5-1 plan adopted December 10, 2025.